PYPD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PY

Mkt Cap

$96.5M

Volume

149.68K

Next Earnings

November 11th

Loading chart

PY

PYPDPolyPid Ltd. Ordinary Shares

PYPD

Pay with—

Available Balance0.00

PY

Mkt Cap

$95.9M

Volume

149.68K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026PolyPid Ltd., a late-stage biopharma company, announced it will report Q4 2025 financial results on February 11, 2026. The company expects to submit its New Drug Application (NDA) for D-PLEX100, its lead product candidate for preventing abdominal colorectal surgical site infections, in early 2026 following positive phase 3 results. A conference call and webcast will be held at 8:30 AM ET on the same day.GlobeNewswire Inc. · Jan 28, 2026

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial ResultsPolyPid, a late-stage biopharma company, announced successful results from its Phase 3 SHIELD II trial for its lead product candidate D-PLEX100, which demonstrated a statistically significant reduction in surgical site infections. The company has secured additional funding of $26.7 million through the exercise of warrants, which is expected to extend its runway beyond the anticipated FDA approval of D-PLEX100.GlobeNewswire Inc. · Jun 16, 2025

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferencePolyPid, a late-stage biopharma company, announced that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025. The company's lead product candidate, D-PLEX100, is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.GlobeNewswire Inc. · Jan 30, 2025

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025PolyPid, a late-stage biopharma company, will report its Q4 and full-year 2024 financial results and operational highlights on February 12, 2025. The company will host a conference call to discuss the results and provide an update on business operations.GlobeNewswire Inc. · Jan 29, 2025

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 MillionPolyPid announced a positive recommendation from the DSMB to continue enrollment of its Phase 3 SHIELD II trial for D-PLEX100, a drug candidate for preventing surgical site infections. The company also announced a $41 million private placement financing to support the trial and potential future regulatory submissions.GlobeNewswire Inc. · Dec 24, 2024

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-CompliancePolyPid, a late-stage biopharma company, has received a notification from Nasdaq regarding its failure to maintain the minimum stockholders' equity requirement for continued listing. The company has 45 days to submit a plan to regain compliance, and expects to do so if warrants from recent private placements are exercised.GlobeNewswire Inc. · Nov 29, 2024

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024PolyPid, a late-stage biopharma company, will report its third quarter 2024 financial results and operational highlights on November 13, 2024. The company will host a conference call and webcast to discuss the results and provide an update on business operations.GlobeNewswire Inc. · Oct 30, 2024

PolyPid to Participate in Three Upcoming Fall Investor ConferencesPolyPid Ltd., a late-stage biopharma company, announced its participation in three upcoming investor conferences, where the management team will present and hold one-on-one meetings.GlobeNewswire Inc. · Sep 3, 2024

PolyPid Announces Private Placement for Up to $14 Million in Gross ProceedsPolyPid, a late-stage biopharma company, announced a $8.1 million private placement financing to fund its ongoing SHIELD II Phase 3 trial of D-PLEX100 for the prevention of abdominal colorectal surgical site infections. The financing extends the company's cash runway into the second quarter of 2025, beyond the anticipated timing for top-line results.GlobeNewswire Inc. · Aug 2, 2024

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 TrialPETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company’s ongoing D-PLEX100 Phase 3 trial. To register, click here.GlobeNewswire Inc. · Jun 10, 2024

to start trading

PY

PYPDPolyPid Ltd. Ordinary Shares

PYPD

Pay with—

Available Balance0.00

Your PositionYou don't own any PYPD yet.

Related Tickers

Earnings